ohhh hell yeahhh !!
In final prototype testing phase on https://t.co/1WvAMhHtn0
Not for public use yet, but im pretty sure you'll find this as cool as I do!
post a random sketch and ill test run it, and we'll see how it goes !!
#orthotwitter#medtwitter
First ever locally injectable immunoactive agent with proven DFS benefit in localized prostate cancer.
Tandem randomized Phase II in surveillance forthcoming.
Origin: Baylor basic science lab (support research!)
https://t.co/gGOjo9eMa5
Another major advance vs cancer! @ASCO#ASCO26
Personalized neoantigen mRNA vaccine 5 year follow-up vs metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda)
https://t.co/NadITTYIT2
Thoughtful review of the PROTEUS trial by @DrSpratticus
First, real credit to the investigators. Pulling off a phase 3 perioperative RCT in localized prostate cancer is a massive undertaking, and easy to forget when you're critiquing from the armchair (mea culpa, I don't run trials like this).
That said, Daniel is essentially pointing out (I think 🤪) that PSMA-PET catches BCR so early that "metastasis-free survival" is really just biochemical recurrence in disguise, and EFS is a lousy surrogate for OS (see his tweetorial for the reasons).
The part that confuses me most: this isn't compared to standard of care. We don't give ADT with prostatectomy. So what are we supposed to do with this information?
https://t.co/JbdeXwbnLj
@DrSpratticus@adamkibel_uro@uretericbud@daviesbj
Hot off the @NEJM press: PROTEUS trial of neoadj ADT/apalutamide with RP from Mary Ellen Taplin et al. First major positive results in this space. And thought provoking editorial from @EAntonarakis. Do you agree??
Plenary presentation at #ASCO26 in about 10 minutes, stay tuned!
https://t.co/8mlljuP38T
https://t.co/sDc0x4h8lK
Hoy, el NEJM publica el ensayo PROTEUS: la apalutamida perioperatoria mejora la respuesta patológica y la supervivencia libre de metástasis en el cáncer de próstata de alto riesgo. ¡Un artículo historico!
Enhorabuena a mi compañero, el Dr. @alvarojuarezs (Urólogo de ICUA), único firmante español del estudio.
Prostate volume doesn't reliably predict obstruction — and we've known it for decades. A new open-access review in PCAN introduces a new concept: periurethral and transition-zone fibrosis is an under-recognised, untreated driver of LUTS/BPH.
The case for antifibrotics: pirfenidone, losartan, PDE5-i, even halofuginone. https://t.co/vIw1BF5CJs
Premature menopause (age <40 years) was associated with a 40% higher lifetime risk of #CoronaryHeartDisease in both Black and White women, supporting its use as a risk-enhancing factor in preventive care. https://t.co/CEoV8jFMU9
Stop a statin and your LDL cholesterol rises 30% in four days. Nobody writes a WSJ feature about it. Stop certain blood pressure medications and your BP can spike within hours. Nobody calls it a design flaw.
Levothyroxine, antidepressants, insulin, metformin, antihistamines. Chronic treatments for chronic conditions, and all of them stop working when you stop taking them. None of them generate think-pieces questioning whether patients should have started.
The AMA classified obesity as a disease in 2013. Thirteen years later, it’s still the only chronic condition where “you have to take it forever” is framed as an argument against treatment rather than a description of how medicine works.
Eli Lilly released retatrutide Phase 3 data yesterday. 28% weight loss in 80 weeks. The most powerful obesity drug that’s ever been tested.
And today the cancer signal drops.
12,112 patients. Seven tumor types. GLP-1 users had half the lung cancer metastasis rate (10% vs 22%). Breast cancer: 43% cut. Colon cancer five-year mortality in a separate study: 15.5% vs 37.1%.
Cancer joins a list that already includes heart disease (SELECT, 20% MACE reduction), kidney failure (FLOW, 24% slower decline), sleep apnea (SURMOUNT-OSA, FDA-approved), addiction (BMJ, 600K veterans, 18-25% reduction across substances), and liver disease (86% fat clearance).
Tumors express GLP-1 receptors. Activate them and NF-kB drops, apoptosis rises. The drug isn’t just shrinking fat. It’s talking directly to the cancer.
One drug class. Designed for blood sugar. The biology keeps finding uses the designers didn’t predict.
#ESTRO26 - 📣 FASTRACKII final results, median F/U of 5 years. Thank you patients, funders, investigators - #kidneycancer#kcsm
1) 100% Local Control: No local recurrences were observed at 36, 60, or 84 months.
2) 100% Cancer-Specific Survival
3) Grade 3 AEs remain at 10%
Until now, physicians using AI in clinic had to assemble the patient’s context themselves. Allergies, comorbidities, medications, prior procedures, copy-pasted in from the chart.
Today we’re announcing a partnership with @CedarsSinai. OpenEvidence now works directly inside Epic, drawing on the patient’s full record and interpreting the medical literature through the lens of that specific patient.
Cedars-Sinai is the first academic health system to deploy patient-aware clinical intelligence at enterprise scale. The clinician asks a complex question in natural language. The answer reflects both the best available evidence and the patient in front of them.
Patient data is never stored after the clinical session or used for any other purpose.